NASDAQ:PHAT

Phathom Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy PHAT

*Your capital is at risk

$10.09

+0.440 (+4.56%)

At Close: Jun 03, 2026

Phathom Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 83.96. In total, the insiders bought 3.38M and sold 365.36K PHAT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	83.96
● Buy	3.38M shares
● Sell	365.36K shares
80% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence May 22, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 83.96. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 03, 2025 Buy	Stock Option (Right to Buy) A-Award	Parikh Asit Director	Director	17 500 Value: $86.6K
Jun 03, 2025 Buy	Common Stock A-Award	Parikh Asit Director	Director	10 500 Value: $52.0K
Jun 03, 2025 Buy	Stock Option (Right to Buy) A-Award	Stenhouse Mark Director	Director	17 500 Value: $86.6K
Jun 03, 2025 Buy	Common Stock A-Award	Stenhouse Mark Director	Director	10 500 Value: $52.0K
Jun 03, 2025 Buy	Stock Option (Right to Buy) A-Award	Fields Heidi Director	Director	17 500 Value: $86.6K
Jun 03, 2025 Buy	Common Stock A-Award	Fields Heidi Director	Director	10 500 Value: $52.0K
Jun 03, 2025 Buy	Stock Option (Right to Buy) A-Award	Topper James N	Director	17 500 Value: $86.6K
Jun 03, 2025 Buy	Common Stock A-Award	Topper James N	Director	10 500 Value: $52.0K
Jun 03, 2025 Buy	Stock Option (Right to Buy) A-Award	Cola Michael F Director	Director	17 500 Value: $86.6K
Jun 03, 2025 Buy	Common Stock A-Award	Cola Michael F Director	Director	10 500 Value: $52.0K
Jun 03, 2025 Buy	Stock Option (Right to Buy) A-Award	Karbe Frank Director	Director	17 500 Value: $86.6K
Jun 03, 2025 Buy	Common Stock A-Award	Karbe Frank Director	Director	10 500 Value: $52.0K
May 21, 2025 Buy	Common Stock P-Purchase	Topper James N Director	Director	3 780 Value: $14.6K
May 21, 2025 Buy	Common Stock P-Purchase	Topper James N Director	Director	3 780 Value: $14.6K
May 19, 2025 Buy	Stock Option (Right to Buy) A-Award	Breedlove Robert Charles Principal Accounting Officer	Officer	33 000 Value: $144.9K
May 19, 2025 Buy	Stock Option (Right to Buy) A-Award	Breedlove Robert Charles Principal Accounting Officer	Officer	33 000 Value: $144.9K
May 14, 2025 Buy	Common Stock P-Purchase	Topper James N Director	Director	6 300 Value: $20.9K
May 14, 2025 Buy	Common Stock P-Purchase	Topper James N Director	Director	6 300 Value: $20.9K
May 13, 2025 Buy	Common Stock P-Purchase	Topper James N Director	Director	1 120 Value: $4K
May 13, 2025 Buy	Common Stock P-Purchase	Topper James N Director	Director	1 120 Value: $4K
May 12, 2025 Buy	Common Stock P-Purchase	Topper James N Director	Director	12 601 Value: $38.3K
May 09, 2025 Buy	Common Stock P-Purchase	Topper James N Director	Director	2 226 Value: $8K
May 09, 2025 Buy	Common Stock P-Purchase	Topper James N Director	Director	33 376 Value: $106.6K
May 09, 2025 Buy	Common Stock P-Purchase	Topper James N Director	Director	33 376 Value: $106.6K
May 09, 2025 Buy	Common Stock P-Purchase	Topper James N Director	Director	2 226 Value: $8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PHATHOM PHARMACEUTICALS, INC.

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal re...

Read Full Profile Here